U.S. trends in the supply of providers with a waiver to prescribe buprenorphine for opioid use disorder in 2016 and 2018
- PMID: 31525570
- DOI: 10.1016/j.drugalcdep.2019.06.029
U.S. trends in the supply of providers with a waiver to prescribe buprenorphine for opioid use disorder in 2016 and 2018
Abstract
Background: Healthcare providers can receive waivers to prescribe buprenorphine for opioid use disorder, an evidence-based medication. The United States federal government has undertaken numerous recent efforts to expand access to waivers. This study describes national trends in the U.S. in 2016 and 2018, geospatial characteristics of waivered providers, and the association of county characteristics with patient treatment capacity.
Methods: Administrative data were drawn for all U.S. counties in 2016 and 2018 for waivered providers, as well as characteristics of counties that may indicate disparities in provider availability. Descriptive statistics were estimated to identify changes across the two years, and how community characteristics correlated with treatment capacity. Measures of geospatial heterogeneity were used to identify spatial clustering.
Results: Nationally the number of waivered providers increased by 175% between 2016 and 2018, and patient capacity increased by 211%. In 2018, 65% of counties had at least one provider, an increase from 54.9% in 2016. Rural counties continued to have relatively fewer providers than metropolitan counties. In both years, counties with higher indicators of the opioid crisis had greater treatment capacity on average. Certain disparities continued to persist in 2018 in terms of patient capacity, as counties in metropolitan areas, those with lower poverty rates and those more physicians per capita had higher capacity on average.
Conclusions: The availability of waivered providers to prescribe buprenorphine increased from 2016 to 2018, while disparities persisted. More research is needed to understand how changes in availability of waivered prescribers impact population health.
Keywords: Buprenorphine; Medication assisted treatment; Opioid agonist therapy; Opioid use disorder.
Published by Elsevier B.V.
Similar articles
-
Where Is Buprenorphine Dispensed to Treat Opioid Use Disorders? The Role of Private Offices, Opioid Treatment Programs, and Substance Abuse Treatment Facilities in Urban and Rural Counties.Milbank Q. 2015 Sep;93(3):561-83. doi: 10.1111/1468-0009.12137. Milbank Q. 2015. PMID: 26350930 Free PMC article.
-
Geographic Distribution of Providers With a DEA Waiver to Prescribe Buprenorphine for the Treatment of Opioid Use Disorder: A 5-Year Update.J Rural Health. 2019 Jan;35(1):108-112. doi: 10.1111/jrh.12307. Epub 2018 Jun 20. J Rural Health. 2019. PMID: 29923637
-
Prescribing Practices of Rural Physicians Waivered to Prescribe Buprenorphine.Am J Prev Med. 2018 Jun;54(6 Suppl 3):S208-S214. doi: 10.1016/j.amepre.2018.02.006. Am J Prev Med. 2018. PMID: 29779544
-
Availability of Medications for the Treatment of Alcohol and Opioid Use Disorder in the USA.Neurotherapeutics. 2020 Jan;17(1):55-69. doi: 10.1007/s13311-019-00814-4. Neurotherapeutics. 2020. PMID: 31907876 Free PMC article. Review.
-
Buprenorphine X-waiver exemption - beyond the basics for the obstetrical provider.Am J Obstet Gynecol MFM. 2021 Nov;3(6):100451. doi: 10.1016/j.ajogmf.2021.100451. Epub 2021 Jul 25. Am J Obstet Gynecol MFM. 2021. PMID: 34320429 Review.
Cited by
-
Exploring the Demographic and Professional Characteristics of Physicians and Nurse Practitioners Associated With Providing Medication-Assisted Treatment: A Retrospective Observational Study.Inquiry. 2024 Jan-Dec;61:469580241237144. doi: 10.1177/00469580241237144. Inquiry. 2024. PMID: 38528773 Free PMC article.
-
A survey of barriers and facilitators to the adoption of buprenorphine prescribing after implementation of a New Jersey-wide incentivized DATA-2000 waiver training program.BMC Health Serv Res. 2024 Feb 8;24(1):179. doi: 10.1186/s12913-024-10648-2. BMC Health Serv Res. 2024. PMID: 38331802 Free PMC article.
-
Differences in perceptions of community stigma towards opioid use disorder between community substance use coalition members and the general public.J Subst Use Addict Treat. 2024 Mar;158:209276. doi: 10.1016/j.josat.2023.209276. Epub 2023 Dec 22. J Subst Use Addict Treat. 2024. PMID: 38142801
-
Differences in medicaid expansion effects on buprenorphine treatment utilization by county rurality and income: A pharmacy data claims analysis from 2009-2018.Drug Alcohol Depend Rep. 2023 Oct 11;9:100193. doi: 10.1016/j.dadr.2023.100193. eCollection 2023 Dec. Drug Alcohol Depend Rep. 2023. PMID: 37876376 Free PMC article.
-
Racial/ethnic disparities in timely receipt of buprenorphine among Medicare disability beneficiaries.Drug Alcohol Depend. 2023 Nov 1;252:110963. doi: 10.1016/j.drugalcdep.2023.110963. Epub 2023 Sep 14. Drug Alcohol Depend. 2023. PMID: 37748421
MeSH terms
Substances
LinkOut - more resources
Full Text Sources